SecBot SecBot
SECBOTREPLAY Home › Report › TEVA

TEVA · The Seventh Circuit reversed the district court's dismissal of Teva's…

TEVA PHARMACEUTICAL INDUSTRIES LTD · COURT-RULING filed Jul 12, 2026 at 20:00 ET

At the news

BULLISHIMPACT 6/10

COURT-RULING filed Jul 12, 2026 at 20:00 ET

The Seventh Circuit reversed the district court's dismissal of Teva's breach-of-contract claim against Eli Lilly, holding that Teva plausibly alleged Lilly violated a 2018 settlement agreement by seeking additional regulatory exclusivity that blocked Teva's generic Forteo entry. The case is remanded for further proceedings, reviving Teva's claim that Lilly's covenants not to obstruct generic competition survived the expiration of the underlying patents.

  • Seventh Circuit reversed dismissal of Teva's breach-of-contract claim against Eli Lilly
  • Teva alleged Lilly violated a 2018 settlement agreement by obtaining 3 years of additional regulatory exclusivity (Nov 2020–Nov 2023) that blocked Teva's generic Forteo entry
  • District court had ruled the settlement agreement expired when Forteo patents expired (Aug 19, 2019); Seventh Circuit found the agreement's duration is a factual question not resolvable on the pleadings
  • Teva's covenant not to sue and other provisions plausibly survived patent expiration, supporting that Lilly's non-obstruction covenant also remained in effect

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access